Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Vaxart, Inc. - Common Stock
(NQ:
VXRT
)
0.3200
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Jul 7, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Vaxart, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Vaxart Could Still Be a Viable Covid 19 Vaccine Play
↗
May 18, 2021
VXRT stock needs to nail the next few studies of its Covid-19 vaccine candidate and prove its thesis to strengthen its bull case.
Via
InvestorPlace
Ocugen or Vaxart: Which Will Take Investors Further?
↗
May 15, 2021
These two high-flying biotechs are vying for the same market.
Via
The Motley Fool
High Cash Burn Will Push Vaxart Stock Down To $1 Per Share
↗
May 14, 2021
Failed clinical trials and high cash burn mean Vaxart is headed down to cash per share levels. That suggests VXRT stock is worth just $1.
Via
InvestorPlace
It Won’t Take Much for Vaxart Stock to Pop Once Again
↗
May 14, 2021
Vaccine stocks are risky, but Americans nervous about a shot might make the difference for VXRT stock
Via
InvestorPlace
Is Vaxart a Buy?
↗
May 12, 2021
Can this troubled coronavirus vaccine developer redeem itself and its investors?
Via
The Motley Fool
Vaxart’s No-Shot Vaccine Is a Potential Game Changer
↗
May 11, 2021
VXRT stock is down from its highs, but there's no need to worry, as Vaxart has a unique Covid-19 vaccine and some encouraging clinical data.
Via
InvestorPlace
Is Vaccine Maker Vaxart Worth Holding From Here?
↗
May 09, 2021
As with most investment decisions, whether to hold depends on the situation. Here are some things to think about.
Via
The Motley Fool
Better Vaccine Stock: Ocugen or Vaxart?
↗
May 07, 2021
Here's how the biotechs compare on several key fronts.
Via
The Motley Fool
12 Health Care Stocks Moving In Thursday's Pre-Market Session
↗
May 06, 2021
Gainers Stealth BioTherapeutics (NASDAQ:MITO) stock moved upwards by 58.33% to $1.9 during Thursday's pre-market session. The market value of their outstanding shares...
Via
Benzinga
30 Stocks Moving in Thursday's Pre-Market Session
↗
May 06, 2021
Gainers Stealth BioTherapeutics Corp (NASDAQ: MITO) shares rose 94.2% to $2.33 in pre-market trading. Stealth BioTherapeutics showcased data for Elamipretide in dry age-related...
Via
Benzinga
58 Stocks Moving In Thursday's Mid-Day Session
↗
May 06, 2021
Gainers Stealth BioTherapeutics Corp (NASDAQ: MITO) shares surged 92.9% to $2.3150. Stealth BioTherapeutics presented at the Association for Research in Vision and Ophthalmology...
Via
Benzinga
Vaxart's Vaccine Candidate Is a Pill, Not a Shot. Does It Matter?
↗
May 06, 2021
If it can reach the market of people that are hesitant to be vaccinated, yes.
Via
The Motley Fool
Vaxart Has 3 Advantages Over Pfizer and Moderna
↗
May 06, 2021
Its coronavirus vaccine candidate may stand out, if upcoming trials are successful.
Via
The Motley Fool
70 Biggest Movers From Yesterday
↗
May 06, 2021
Gainers Nemaura Medical Inc. (NASDAQ: NMRD) shares surged 135.3% to close at $11.06 on Wednesday after the company receipt of a purchase order for 5,000 sugarBEAT transmitters...
Via
Benzinga
64 Biggest Movers From Yesterday
↗
May 05, 2021
Gainers Cocrystal Pharma, Inc. (NASDAQ: COCP) shares surged 72.6% to close at $2.14 on Tuesday. Cocrystal Pharma recently announced progress on its COVID-19 antiviral drug...
Via
Benzinga
Why Vaxart Stock Is Surging Today
↗
May 04, 2021
Investors are excited about the company's experimental COVID-19 vaccine.
Via
The Motley Fool
44 Stocks Moving In Tuesday's Mid-Day Session
↗
May 04, 2021
Gainers Cocrystal Pharma, Inc. (NASDAQ: COCP) shares jumped 75.4% to $2.1750. Cocrystal Pharma recently announced progress on its COVID-19 antiviral drug candidates that target...
Via
Benzinga
Why Vaxart Shares Popped 78% in April
↗
May 04, 2021
Shareholders keep getting their hopes up for the company's tablet-based COVID-19 vaccine.
Via
The Motley Fool
Vaxart Stock Is Surging As Its Oral COVID-19 Vaccine Can Potentially Trigger Immunity Against Variants
↗
May 04, 2021
Vaxart Inc has announced new data from the Phase 1 trial evaluating its oral COVID-19 vaccine candidate, dubbed as VXA-CoV2-1.
Via
Talk Markets
The Daily Biotech Pulse: Vaxart Rebounds On Strong Vaccine Data, Pfizer's Beat-And-Raise Quarter, BioLineRx Data
↗
May 04, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 3) AbbVie Inc. (NYSE: ABBV)...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
↗
May 04, 2021
Gainers BioLine Rx (NASDAQ:BLRX) shares moved upwards by 65.2% to $5.27 during Tuesday's pre-market session. The market value of their outstanding shares is at $226.7...
Via
Benzinga
Vaxart Stock Is Surging As Its Oral COVID-19 Vaccine Can Potentially Trigger Immunity Against Variants
↗
May 04, 2021
Vaxart Inc (NASDAQ: VXRT) has announced new data from the Phase 1 trial evaluating its oral COVID-19 vaccine candidate, dubbed as VXA-CoV2-1. Data obtained...
Via
Benzinga
26 Stocks Moving in Tuesday's Pre-Market Session
↗
May 04, 2021
Gainers Cocrystal Pharma, Inc. (NASDAQ: COCP) shares rose 60.5% to $1.99 in pre-market trading. Cocrystal Pharma recently announced progress on its COVID-19 antiviral drug...
Via
Benzinga
52 Biggest Movers From Yesterday
↗
May 04, 2021
Gainers Regional Health Properties, Inc. (NYSE: RHE) shares climbed 102.5% to close at $14.62 on Monday after jumping 38% on Friday. Image Sensing Systems, Inc. (NASDAQ: ISNS)...
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
↗
May 03, 2021
Gainers Precipio (NASDAQ:
Via
Benzinga
Vaxart Slides After Reporting Delay Of Trial For Potential COVID-19 Oral Vaccine
↗
May 03, 2021
Shares of Vaxart are under pressure on Monday after the company reported worse-than-expected first quarter losses and said that its Phase II trial of VXA-CoV2-1 is now expected to start mid-year 2021...
Via
Talk Markets
Mid-Afternoon Market Update: Crude Oil Rises 1.5%; AVROBIO Shares Plummet
↗
May 03, 2021
Toward the end of trading Monday, the Dow traded up 0.82% to 34,152.49 while the NASDAQ fell 0.36% to 13,912.07. The S&P also rose, gaining 0.41% to 4,198.29. The U.S. has the...
Via
Benzinga
Topics
Stocks
2 Biopharma Stocks Looking To Make A Difference Against COVID-19: Technical Levels To Watch
↗
May 03, 2021
Shares of Ocugen Inc. and Vaxart Inc. are moving Monday, May 3. Ocugen shares gapped higher after the company's studies showed that COVAXIN is potentially effective against three key variants of...
Via
Talk Markets
Vaxart Stock Plummets On Growing Losses As Investors Eye Covid Pill
↗
May 03, 2021
Vaxart stock plummeted Monday ahead of a key presentation for its oral Covid vaccine and after the company reported growing first-quarter losses.
Via
Investor's Business Daily
12 Health Care Stocks Moving In Monday's Intraday Session
↗
May 03, 2021
Gainers Precipio (NASDAQ:PRPO) stock moved upwards by 111.42% to $3.85 during Monday's regular session. The current volume of 113.0 million shares is 18552.84% of...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.